Sun Pharma Advanced Research Company to raise up to Rs 1800 crore
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Wednesday said it will seek shareholders' approval to raise up to Rs 1,800 crore through various modes, including issue of equity shares and securities.
The company proposes to raise the funds in one or more tranches, by way of public / private offerings, qualified institutional placement, rights offering or any other permissible mode, SPARC said in a regulatory filing.
The approval is being sought for raising funds for an aggregate consideration of up to Rs 1,800 crore or in equivalent foreign currency, SPARC said.
The company seeks shareholders' nod to raise the funds by way of issuing equity shares, convertible warrants, preference shares/ bonds /debentures /any other instruments whether convertible into equity or not, American Depository Receipts, Global Depository Receipts, Foreign Currency Convertible Bonds.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.